EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Photoelectron Corp (PECN) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Photoelectron Corp $0.18, price $1.07, upside -83.2%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

PC Photoelectron Corp logo Thin data Jun 23, 2026

Photoelectron Corp

PECN · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.1800 · Strongly overvalued (−83.2%)
!Quality 26/100
!Mixed Growth (revenue 3y +13.7 %/yr)
!Negative equity (buybacks among others)
!Trails peers (1/5)
!Evidence only low, so the estimate is less certain
Watch Photoelectron Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.32 $0.0001 Fair Value $0.1800 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range $0.0001 – $1.32 · fair‑value band $0.1300 – $0.2200 · the $1.07 price screens above the $0.1800 fair value. Dashed = 300-day average. As of Jun 23, 2026.

Follow Photoelectron in your weekly email

Every Wednesday you see whether Photoelectron is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Photoelectron Corporation, a technology company, engages in the development, manufacture, and marketing of miniature x-ray systems for multiple market applications. It creates and adapts miniature x-ray systems for various applications in healthcare and nonhealthcare related markets.

Show more

Photoelectron Corporation, a technology company, engages in the development, manufacture, and marketing of miniature x-ray systems for multiple market applications. It creates and adapts miniature x-ray systems for various applications in healthcare and nonhealthcare related markets. The company offers micro-adaptive x-ray systems designed for x-ray fluorescence analysis, intravascular radiation therapy, brachytherapy, radiosurgery, intraoperative radiation therapy, and instrumentation to the industrial and medical markets through original equipment manufacturers. Photoelectron Corporation was founded in 1989 and is based in North Billerica, Massachusetts.

Stock analysis

Photoelectron Corp (PECN) currently trades at $1.07, while our model-based Fair Value estimate is $0.1800, 83.2% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 84/100, which puts the evidence level at low.

Scenario range: $0.1300 (bear) to $0.2200 (bull), the price of $1.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Photoelectron Corp reported revenue of $996K in FY2001 versus $678K in FY1998, a compound +13.7%/yr. Reported net income was −$9.1M in FY2001.

Key figures

Market cap $20.1M · P/S ratio 14.3 · EPS (TTM) $−0.0100 · Return on assets (EBIT) −129% · Operating margin −498% · Revenue (TTM) $1.4M · Revenue growth (YoY) +98.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 19% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −83%, PECN screens richer than that median.

Notify me when PECN reaches fair value

Put PECN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 26/100

Of which business quality 21 · Market factors (momentum, volatility) 56

Profitability 2
Margins and returns on capital today
Quality Growth 5
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 33
Balance sheet, leverage, solvency risk
Investment 73
Disciplined investing over empire-building
Low Volatility 80
Calm price path (market factor)
Momentum 46
Price trend over the last 3–12 months (market factor)
52W Momentum 45
Distance to the 52-week high (market factor)

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−30.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,200.7% (1998) → −833.1% (2001)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
not computed

PECN screens overvalued: fair value 83% below the price. Compare with Abbott Laboratories, →

Compare Photoelectron Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −83.5% · Bottom 25%
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −78.8% · Bottom 25%
Growth and dividend
Revenue growth 98.8% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 14.35× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 9
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 11
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Photoelectron Corp · Fair Value
$0.1800 −83%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Photoelectron Corp Fair Value". https://www.fairvalue-calculator.com/stock/PECN

Frequently asked questions

Is Photoelectron Corp (PECN) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.1800 versus a price of $1.07, about −83% upside (overvalued).
What is the fair value of PECN?
Our model-based fair value for Photoelectron Corp is $0.1800 (as of Jun 23, 2026), built from audited fundamentals. The current price: $1.07.
What is the quality score of PECN?
Photoelectron Corp has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Photoelectron Corp (PECN)?
Our model-based price target is the fair value of $0.1800 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario $0.1300, optimistic scenario $0.2200. It is a calculation from audited fundamentals, not an analyst target.
What is the Photoelectron Corp stock forecast for 2026?
Our models put fair value at $0.1800, about −83% upside versus a price of $1.07 (overvalued). Cautious scenario $0.1300, optimistic scenario $0.2200. The calculation is refreshed regularly with new filings.
What is the revenue of Photoelectron Corp (PECN)?
Photoelectron Corp reported trailing-twelve-month revenue of about $1.4M (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of Photoelectron Corp (PECN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Photoelectron Corp it is $0.1800 per share (as of Jun 23, 2026), against a price of $1.07. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Photoelectron Corp stock overvalued or undervalued in 2026?
As of Jun 23, 2026, PECN trades above its calculated fair value: price $1.07, fair value $0.1800, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PECN?
No. The price is what the market pays today ($1.07); the fair value is what the company's own numbers justify ($0.1800). For Photoelectron Corp the two are $0.8920 per share apart. That gap is exactly why we show both numbers side by side.
How much is Photoelectron Corp worth?
The market values Photoelectron Corp at about $20.1M (market capitalisation, as of Jun 23, 2026). Per share that is $1.07; our models calculate a fair value of $0.1800 per share.
What do the bullish and bearish scenarios say about PECN?
Our models span a range for Photoelectron Corp: cautious scenario $0.1300, base $0.1800, optimistic $0.2200 per share (as of Jun 23, 2026, price $1.07). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Photoelectron Corp (PECN)?
Balance-sheet figures for Photoelectron Corp (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is PECN from its 52-week high?
Photoelectron Corp trades at $1.07, about 19% below its 52-week high of $1.32 and 24% above the low of $0.8666 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1800 is for.
Which stocks are comparable to Photoelectron Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Photoelectron Corp stock attractive at the current price?
The data as of Jun 23, 2026: price $1.07, calculated fair value $0.1800 (−83%), Quality Score 26/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PECN calculated?
We run Photoelectron Corp through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Photoelectron Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Photoelectron Corp (PECN)?
The closing price on Oct 2, 2026 was $1.07. Our model-based fair value is $0.1800, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Photoelectron Corp right now?
The price sits above even our optimistic bull case ($0.2200). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Photoelectron Corp

How large is the market capitalisation of Photoelectron Corp (PECN)?
The market capitalisation of Photoelectron Corp is $20.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Photoelectron Corp (PECN)?
The price-to-sales ratio of Photoelectron Corp is 14.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Photoelectron Corp (PECN)?
Earnings per share at Photoelectron Corp are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Photoelectron Corp (PECN)?
On an EBIT basis the return on assets of Photoelectron Corp is −129% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Photoelectron Corp (PECN)?
The operating margin of Photoelectron Corp is −498% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Photoelectron Corp (PECN)?
Revenue at Photoelectron Corp is growing +98.8% versus a year earlier (3y avg +13.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed

Watch Photoelectron Corp in the live analysis

One click puts Photoelectron Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.